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ABSTRACT  39 
BACKGROUND: T helper type 2 cell-released interleukin 31 (IL-31) is a critical mediator 40 
in atopic dermatitis (AD), a prevalent and debilitating chronic skin disorder. Brain-derived 41 
natriuretic peptide (BNP) has been described as a central itch mediator. The importance of 42 
BNP in peripheral (skin-derived) itch and its functional link to IL-31 within the neuro-43 
immune axis of the skin is unknown.   44 
OBJECTIVE: To investigate the function of BNP in the peripheral sensory system and 45 
skin in IL-31-induced itch and neuro-epidermal communication in AD.  46 
METHODS: Ca2+-imaging, immunohistochemistry, quantitative real-time PCR, RNA-Seq, 47 
knockdown, cytokine/phosphor-kinase arrays, enzyme immune assay and pharmacological 48 
inhibition were subjected to examine the cellular basis of the IL-31-stimulated, BNP-49 
related itch signaling in human DRG neurons (hDRG) and skin cells, transgenic AD-like 50 
mouse models, and  human skin of AD and healthy subjects.  51 
RESULTS: In hDRG, we confirmed expression and co-occurrence of OSMRβ and IL-31 52 
receptor A in a small subset of neuronal population. Furthermore, IL-31 activated ~50% of 53 
endothelin-1-responsive neurons, and half of the latter also responded to histamine. In 54 
murine DRGs IL-31 upregulated Nppb and induced SNARE-dependent BNP release. In the 55 
Grhl3PAR2/+mice, house dust mite-induced severe AD-like dermatitis was associated with 56 
Nppb upregulation. Lesional IL-31Tg mice also exhibited increased Nppb transcripts in 57 
DRGs and skin; accordingly, skin BNP receptor was elevated. Importantly, expression of 58 
BNP and its receptor were increased in AD patient skin. In human skin cells, BNP 59 
stimulated a pro-inflammatory, itch-promoting phenotype.    60 
CONCLUSION: Our findings show, for the first time, that BNP is implicated in AD and 61 
that IL-31 regulates BNP in both DRGs and skin. IL-31 enhances BNP release and 62 
synthesis, and orchestrates cytokine and chemokine release from skin cells, thereby 63 
coordinating the signaling pathways involved in itch.  Inhibiting peripheral BNP function 64 
may be a novel therapeutic strategy for AD and pruritic conditions.  65 
 66 
  67 
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KEY MESSAGES 68 
 69 
• IL-31 induces SNARE-dependent BNP release and its synthesis in sensory nerves. 70 
• BNP increases AD-related cytokine release from keratinocytes and dendritic cells 71 
through GSK3-dependent and C-Jun activation pathways, respectively. 72 
• AD is associated with upregulation of BNP and its receptor. 73 
 74 
 75 
CAPSULE SUMMARY 76 
 77 
Our study provides a novel functional link between IL-31 and BNP within the neuro-78 
immune axis of AD. Blockade of BNP release by inactivating SNAREs offers new strategy 79 
for management of AD and pruritic conditions.  80 
 81 
 82 
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ABBREVIATIONS USED 100 
AD                             atopic dermatitis 101 
BNP                           brain-derived natriuretic peptide  102 
Calca                         calcitonin gene-related peptide (CGRP) gene 103 
CCL20                       C-C Motif Chemokine Ligand 20 104 
CXCL                        chemokine (C-X-C motif) ligand  105 
DAPI                          4',6-diamidino-2-phenylindole  106 
DRGs                         dorsal root ganglionic neurons  107 
ET-1                           endothelin-1 108 
FPKM                        fragments per kilobase of transcript per million mapped reads  109 
GSK3                         glycogen synthase kinase 3  110 
hDCs                          human  dendritic cells 111 
hKCs                          human primary keratinocytes  112 
HDM                          house dust mite 113 
IL-31                          interleukin-31  114 
IL-31RA                     interleukin-31 receptor alpha 115 
IL-31Tg mice             IL-31-transgenic mice 116 
       MMP9                        plasma matrix metalloproteinase-9 117 
         NeuN antibody           NEUronal Nuclei antibody 118 
Nppb                          BNP gene 119 
         NPR1                         natriuretic peptide receptor A 120 
         NPR2                         natriuretic peptide receptor B 121 
         OSMRβ                     oncostatin M receptor beta subunit  122 
         PGP9.5                      protein gene product 9.5 123 
         RT-PCR                     real-time PCR 124 
         SNAP-25                    synaptosomal associated protein 25k 125 
         SNARE                      soluble N-ethylmaleimide-sensitive factor activating protein receptor  126 
         STX1                          syntaxin 1 127 
Tac-1                          substance p (SP) gene 128 
TG                              trigeminal ganglia 129 
Th2                             T helper type 2  130 
TSLP                          thymic stromal lymphopoietin  131 
VAMP                        vesicle-associated membrane protein 132 
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V1                              vesicle-associated membrane protein isoform 1 133 
V7                              vesicle-associated membrane protein isoform 7 134 
WT                             wild-type  135 
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INTRODUCTION 136 
Atopic dermatitis (AD) is one of the most prevalent chronic inflammatory skin diseases 137 
world-wide. It is characterized by dysregulation of immunity, skin barrier as well as nerve 138 
function, resulting clinically in eczema and itch (1-4). The mediators of histamine-139 
independent itch in AD are poorly understood (5). Candidates include endothelin-1 (ET-1), 140 
thymic stromal lymphopoietin (TSLP) and the cytokines interleukin (IL)-4, IL-13 and IL-141 
31 (1). IL-31 is a critical cytokine in the pathophysiology of AD (1, 6, 7) playing a role in 142 
eczema (7), itch (8), and nerve growth (9). Elevated serum levels of IL-31 were found to 143 
correlate with disease severity in patients (6, 10). IL-31 serves as a critical neuron-immune 144 
link between T helper type 2 (Th2) cells and sensory nerves in the generation of T cell–145 
mediated itch (8). Cutaneous and intrathecal injections of IL-31 evoked robust itch 146 
behavior in mice (8).  IL-31 injection in mouse cheek induces itch, but not pain (8). IL-31-147 
transgenic (Tg) mice that overexpress IL-31 develop severe pruritus and skin lesions 148 
similar to AD (7). In mice, IL-31 receptor A (IL-31RA) associates with oncostatin M 149 
receptor β (OSMRβ) to form the IL-31RA heterodimeric complex that binds to IL-31 (8). 150 
Targeting IL-31 pathway therapeutically has been proved to be effective in AD (11, 12).  151 
For examples, IL-31 neutralization in AD-models was effective in the treatment of IL-31-152 
induced itch and dermatitis (13-17). Anti-IL-31RA antibody nemolizumab was evaluated in 153 
phase II with satisfied efficacy and safety for the treatment of patients with moderate-to 154 
severe AD disease (11). Despite this, it is not known if IL-31 stimulates neuropeptide 155 
release from central and/or peripheral primary afferent neurons to modulate itch 156 
transmission in skin and/or spinal cord. The importance of IL-31 in the regulation and 157 
release of neuropeptides from peripheral sensory nerves in the skin and the resulting 158 
neurogenic inflammation in AD, also remains elusive.   159 
B-type natriuretic peptide (BNP) is a 32-amino-acid cyclic peptide expressed in a subset of 160 
primary afferent neurons (18-20). It binds to the natriuretic peptide receptor A (NPR1) and 161 
to a lesser extent NPR2 (21). BNP is the Nppb gene product and has been identified as an 162 
important neuropeptide for itch transmission from the sensory to the spinal cord (19).  163 
Intrathecal injection of BNP in mice induced a robust itch phenotype whereas Nppb -/- mice 164 
exhibited lack of scratching responses to many puritogens (19). In contrast to substance P 165 
(SP) and calcitonin gene-related peptide (CGRP) which facilitate pain processing and 166 
painful neurogenic vasodilation in mice, BNP has been characterized as a negative 167 
regulator of nociceptive transmission (20, 22). Nppb has been detected in the murine 168 
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primary puritogenic sensory dorsal root ganglionic neurons (DRGs), which overlapped with 169 
IL-31RA+ neurons (23). Despite of its importance in itch, it is unknown whether BNP can 170 
be released from peripheral sensory neurons in response to puritogens (i.e. IL-31 or 171 
histamine). The cellular and molecular basis for its pruritic action on skin and immune cells 172 
also remains unknown. Understanding the downstream signaling pathways of IL-31 and its 173 
potential interacting mediators like BNP, CGRP or SP is significant because it will not only 174 
expand our current knowledge and theoretical repertoire but may also aid the development 175 
of a more efficacious treatment for chronic skin inflammation and pruritus. Herein, we 176 
investigated the possible mechanistic relationship between IL-31 and BNP in itch. The aim 177 
of the current study was to: (i) examine the expression and function of IL-31 receptor in 178 
human DRGs (hDRGs); (ii) investigate the role of BNP in AD using mice models and 179 
human subjects; (iii) investigate IL-31-induced release of BNP and other neuropeptides in 180 
relation to itch; (iv) dissect the molecular components of the exocytotic machinery in IL-181 
31-induced BNP release; (v) study the alteration of BNP receptor in AD skin; (vi) screen 182 
distinct intracellular kinases activated and cytokines induced by BNP in human skin cells. 183 
Overall, our results reveal a novel IL-31-mediated downstream target in itch induction and 184 
highlight the importance of BNP as a potential target for the treatment of AD and other itch 185 
disorders.  186 
 187 
MATERIALS and METHODS 188 
Materials 189 
Human skin samples from 3 donors of AD and 3 donors of healthy control subjects were 190 
bought from Tissue Solutions Ltd., Glasgow, Scotland. Human DRG paraffin sections were 191 
purchased from Amsbio (Local distributor of Zyagen Laboratories). Antibodies, cells and 192 
reagents for tissue culture and others are detailed in the Supplementary Material and 193 
Methods. 194 
 195 
Human and animal rights 196 
Human DRGs were isolated as previously described (24) with full legal consent by Anabios 197 
Corporation (San Diego, CA, USA). DRGs were isolated and cultured from 1 donor (25 198 
year old Hispanic female). Housing/handling of mice (C57BL6), IL-31Tg mice and 199 
experimental procedures had been approved by the University College Dublin Ethics 200 
Committee and the Irish Authorities. Housing/handling of Grhl3PAR2/+ transgenic mice 201 
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model and experimental procedures following federal guidelines had been approved by the 202 
University of California, San Francisco Ethics Committee and by local authorities. 203 
 204 
HDM application on Grhl3PAR2/ + mouse model 205 
The Grhl3PAR2/ + mice were maintained in C57BL6/J-129X1/SvJ mixed strain and used 206 
for the experiments as an AD model. For details of HDM treatment, see Supplementary 207 
Material and Methods. 208 
 209 
RNA-Seq  210 
For gene expression experiment, trigeminal ganglia (TG) were harvested from wild-type 211 
(WT) and HDM-treated Grhl3PAR2/+ mice and processed for RNA-Seq. For details, see 212 
Supplementary Material and Methods. 213 
 214 
Quantitative real time PCR (RT-PCR) 215 
RNA was isolated from cultured mouse DRG neurons (mDRGs) using the RNeasy kit 216 
(Qiagen, Hilden, Germany). TRIzol Reagent was used to isolate RNA from DRGs and 217 
skins of WT and IL-31Tg mice. The quantitation of mRNA levels was performed by real 218 
time fluorescence detection using SYBR Green ROX mix (ABI). For details, see 219 
Supplementary Material and Methods. 220 
 221 
BNP, CGRP and SP release assay 222 
For detailed preparation of mDRGs culture and their release of neuropeptides, see 223 
Supplementary Material and Methods. 224 
 225 
Measurement of intracellular Ca2+ concentration 226 
Human DRGs (hDRGs) and mDRGs in culture were loaded with calcium indicator before 227 
measurement of Ca2+ mobilization in response to various pruritogens. For details, see 228 
Supplementary Material and Methods. 229 
 230 
Immunofluorescence staining  231 
Cultured mDRGs, paraffin sections of human DRG and skin (15µm) were stained and 232 
imaged by a Zeiss LSM710 confocal microscope (Carl Zeiss MicroImaging). For details, 233 
see Supplementary Material and Methods. 234 
 235 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
Lentivirus-mediated knockdown of soluble N-ethylmaleimide-sensitive factor 236 
activating protein receptors (SNAREs) 237 
Cultured mDRGs in 7d in vitro were treated with non-targeted control lentiviral particles or 238 
shRNA lentivirus specifically targeting to SNAREs for 7-10 days before measuring BNP 239 
release and protein expression. For details, see Supplementary Material and Methods. 240 
 241 
Culture of human primary epidermal keratinocytes (hKCs) and human monocyte-242 
derived dendritic cells (hDCs), cytokine antibody array and phosphor-kinase array 243 
hKCs were cultured in the KBM-Gold™ medium with KBM-Gold SingleQuot KCs 244 
supplement (Lonza). hDCs were cultured by in vitro differentiation of CD14+ monocytes 245 
using LGM-3™ Lymphocyte Growth Medium plus 50 ng/ml GM-CSF and 50 ng/ml IL-4 246 
(Lonza). Cells were maintained in the above medium for 3 d before use. For detailed 247 
cytokine antibody and phosphor-kinase arrays, see Supplementary Material and Methods. 248 
 249 
Statistical Data Analysis 250 
Data expressed as mean ± S.E.M. n ≥ 3 independent experiments, probability values are 251 
determined with the use of Student’s 2-tailed t test; P values <0.05 are considered 252 
significant; non-significant N.S. P>0.05; *P < 0.05; **P < 0.01; *** P<0.001. Data analysis 253 
was performed with Prism software. 254 
 255 
RESULTS 256 
 257 
IL-31RA and OSMRβ are co-expressed in a small subset of human DRG neurons  258 
In human AD, IL-31 levels correlate with disease severity (6, 10). However, 259 
subpopulations responding to IL-31 and distribution of its receptors (IL-31RA and 260 
OSMRβ) in hDRGs have not been fully characterized. Our study herein will help to define 261 
the functional contribution of neuronal subpopulations to the skin inflammation of AD in 262 
humans. Using double-immunohistochemistry, we observed IL-31RA and OSMRβ 263 
expression in hDRG sections (Fig 1A-D). IL-31RA was detected in ~3% of total neurons 264 
visualized with a neuronal marker NEUronal Nuclei (NeuN) antibody, which stained 265 
strongly neuronal nuclei and distal cytoplasm (Fig 1A). IL-31RA also occurred in a small 266 
proportion of cells immunoreactive to protein gene product 9.5 antibody (PGP9.5) (Fig 1B), 267 
another marker for sensory nerves. Similarly, OSMRβ was found in a small subset of 268 
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PGP9.5+ neurons (Fig 1C). Co-staining of IL-31RA and OSMRβ confirmed that in hDRG 269 
all of IL-31RA+ neurons were OSMRβ+ (Fig 1D, E). However, ~5% OSMRβ+ neurons did 270 
not appear to be strongly labeled by anti-IL-31RA (Fig 1D arrowed neuron).  271 
 272 
IL-31 induces intracellular calcium mobilization in a distinct subset of hDRGs, which 273 
also responds to ET-1 274 
Functional identities of neuronal subsets were further assayed in hDRG using intracellular 275 
Ca2+ imaging upon application of individual or combined puritogens to cultured hDRGs. 276 
We found that  ~4% hDRG neurons were directly activated by ET-1 (n=100 neurons) (Fig 277 
2A, B top panels). The response consisted of a transient increase in intracellular calcium. In 278 
comparison, glia cells consistently exhibited large responses with slow kinetic. In several 279 
cases after ET-1 application, glial cells generated oscillatory calcium signals that persisted 280 
even after the washout of ET-1 (Fig 2A, B top panels). In our observation, about ~50% of 281 
neurons pre-exposed to ET-1 also responded to histamine (Fig 2A middle panel and C). 282 
Following application of ET-1 and histamine some neurons exhibited spontaneous calcium 283 
transients. Co-application of ET-1 and histamine did not potentiate the response. On the 284 
contrary, de-sensitization was apparent in some neurons (Fig 2A bottom panel). For the IL-285 
31-induced response, 1 of 50 neurons pre-exposed to ET-1 responded with a rapid calcium 286 
transient to IL-31 (Fig 2B top and middle panels). Likewise, co-application of ET-1 and IL-287 
31 did not potentiate the response, except in one neuron with a delayed response (Fig 2B 288 
bottom panel). In summary, ~50% neurons responded to histamine, and ~4% of total 289 
neurons responded to ET-1. Half of the ET-1-responsive neurons also responded to 290 
histamine (Fig 2C). Overall, in hDRGs 2% of neurons were responding to IL-31, and these 291 
cells also responded to ET-1 (Fig 2C). Due to the importance of IL-31 and ET-1 in 292 
pathogenesis of AD, it is tempting to postulate that this neuronal subset mediates itch 293 
transmission in humans. 294 
We further investigated whether murine DRGs (mDRGs) exhibit similar phenomenon in 295 
response to IL-31 and ET-1. Cultured mDRGs uploaded with Fluo-4AM were treated with 296 
IL-31 and ET-1, sequentially. In a total of 335 neurons recorded, IL-31 activated 9 neurons 297 
(~2.7%) and ET-1 activated 14 neurons (~4.2 %). 5 IL-31-responsive neurons did not 298 
respond to ET-1 (Fig 2D.). Thus, similarities as well as differences were observed between 299 
human and murine DRG with respect to IL-31 and ET-1 stimulation.   300 
 301 
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PAR2 transgenic mice treated with house dust mite (HDM) and IL-31Tg mice are 302 
associated with Nppb upregulation in sensory nerves  303 
We investigated the possible involvement of BNP in AD using Grhl3PAR2/+ mice (25). 304 
These mice develop atopic-like inflammation, scaly dry skin, epidermal hyperplasia, and 305 
itch behaviors, all characteristics of human AD (25). We applied HDM on the right cheek 306 
to induce severe dermatitis, as HDM have abundant proteases that can activate PAR2 307 
constantly and stably. Ipsilateral (ipsi) and contralateral (contra) trigeminal ganglia (TG) 308 
from each mouse were analyzed by RNA-Seq (Fig 3A). Clinical scores for pathologic 309 
diagnosis (skin lesion severity) were evaluated by hematoxylin and eosin (HE) staining on 310 
cheek skin biopsy from each of the 8 HDM-applied mice and vehicle-treated WT mice 311 
(representative images shown in Fig 3B). Notably, in HDM-treated mice, the correlation 312 
coefficient between clinical score and fold-change of fragments per kilobase of transcript 313 
per million mapped reads (FPKM) for Nppb transcripts (ipsi/contra) is about 0.8 (Fig 3A). 314 
Average of fold change of Nppb for these 8 mice is ~2.3. In contrast, HDM did not induce 315 
significant change in TGs for NPR1, NPR2, IL-31, IL-31RA, and OSMR in Grhl3PAR2/+ 316 
mice (Fig 3A). After comparing FPKM from TGs of ipsilateral (right cheek) vs 317 
contralateral (left cheek) in 3 high clinical score Grhl3PAR2/+ mice (score was 8, 7, 7), we 318 
found that Nppb transcripts were upregulated by 3.5 times by application of HDM and 319 
ranked the third position among the highly upregulated genes (Fig 3C). Notably, the Nppb 320 
FPKM values in the contralateral (left) cheek of Grhl3PAR2/+ mice were not significantly 321 
different from that of WT mice with or without vehicle (Vaseline) treatment 322 
(Supplementary Fig E1).    323 
As IL-31Tg mice show skin phenotype closely resembling those of human AD (7), we used 324 
RT-PCR to compare Nppb transcripts in whole DRG tissue isolated from the IL-31Tg  325 
(lesional and non-lesional) and from age matched WT non-transgenic mice. Higher levels 326 
of Nppb mRNA were detected in the DRGs isolated from both lesional and non-lesional IL-327 
31Tg mice (Fig 3D).  328 
Collectively, our data indicate that BNP is implicated in AD and may be associated with 329 
severity of AD-like skin conditions in mice.   330 
 331 
IL-31 augments release and upregulates synthesis of BNP but not CGRP or SP from 332 
cultured mDRGs  333 
IL-31 directly activates peripheral sensory neurons to induce pruritus (8); however, its 334 
effect on BNP has not yet been reported. To explore this possibility, we cultured mDRGs 335 
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and incubated neurons with 300 nM IL-31 for 30 min before starting the release assay. The 336 
IL-31-inducd release was compared with the response to histamine, high (HK, 60 mM) and 337 
low (LK, 3.5 mM) potassium chloride buffers (Fig 4A). Notably, IL-31 elicited ~2.7 fold 338 
increase of BNP release over the basal level (LK). Histamine (His) and potassium 339 
depolarization (HK) also elicited BNP release (Fig 4A). Moreover, IL-31-induced BNP 340 
release was concentration- (Fig 4B) and time- (Fig 4C) dependent. No significant 341 
difference of BNP release (Fig 4B) and mRNA synthesis over 30 min (Supplementary Fig 342 
E2 A) was detected between 300 nM and 1 µM concentrations of IL-31. RT-PCR results 343 
revealed that 300 nM IL-31 induced Nppb mRNA synthesis peaked at 4h and declined at 8h 344 
(Supplementary Fig E2 B). In contrast, neither CGRP nor SP release was affected by IL-31 345 
or His, although both were elicited by HK (Fig 4D). This finding demonstrates for the first 346 
time that IL-31 directly activates sensory neurons to release BNP rather than CGRP or SP. 347 
Consistently,  incubation of mDRGs with IL-31 for 6h did not induce significant changes of 348 
mRNA levels of Calca (CGRP gene) or Tac-1 (SP gene) (Fig 4E). In contrast, IL-31 349 
increased Nppb mRNA levels by ~2 fold. Altogether, these findings confirm that IL-31 350 
directly induces BNP release and upregulates its synthesis, indicating BNP might 351 
contribute to IL-31-mediated itch signaling.  352 
Subsequently, we performed immunofluorescence studies using antibodies against BNP or 353 
CGRP with their specificities verified (Supplementary Fig E3) to investigate their 354 
expression and distribution pattern in mDRGs. Notably, BNP was expressed in both 355 
CGRP+- and CGRP- - neurons (Fig 4F). This distinct, but overlapping distribution, suggests 356 
that BNP and CGRP may have discrete functional roles in the transduction of itch 357 
signaling. 358 
 359 
IL-31-induces BNP release from cultured mDRGs via a SNARE-mediated vesicle 360 
fusion 361 
BNP release from sensory neurons in response to itch stimuli might be regulated by 362 
selective exocytotic machinery. In terms of IL-31-induced BNP release, its mechanism is of 363 
particular importance because of its relevance in AD. SNAREs are critical membrane 364 
fusion proteins and serve as therapeutic targets for many neurological diseases (26). To 365 
explore their role in BNP release, SNAP-25 (synaptosomal-associated protein 25k) and two 366 
other vesicular SNARE proteins, vesicle-associated membrane protein (VAMP) isoform 1 367 
(V1)   and 7 (V7), were selectively knocked down using lentiviral shRNA particles. 368 
Notably, expression levels of each protein were substantially reduced compared to the non-369 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
targeted controls (Fig 5A). Knockdown of SNAP-25 and V1, but not V7, resulted in 370 
complete blockade of IL-31-elicited BNP release (Fig 5B). These findings, for the first 371 
time, demonstrated that selective SNARE proteins control IL-31-induced BNP release.  372 
 373 
Expression of BNP and its receptors is increased in the skin of patients with atopic 374 
dermatitis  375 
To understand BNP-induced signaling and identify the functional consequence of BNP in 376 
human skin level, we examined the expression of BNP and its receptor NPR1 and NPR2 in 377 
cultured human keratinocytes (hKCs). Using immunostaining, we readily detected 378 
expression of NPR1 and NPR2 in cultured hKCs (Supplementary Fig E4 A). Both receptors 379 
showed punctate distribution. In a great contrast, BNP immune-signal was below the 380 
detection limit in these cultured cells (Supplementary Fig E4 A).  381 
Next, similar experiments were performed on human skin sections from AD subjects and 382 
healthy controls. We found that in the epidermis, no staining of BNP was discernible in 383 
normal skin, similar to the observation in cultured KCs, but it was readily detected in AD 384 
skin (Fig 6A), indicating a disease-related upregulation of BNP expression. We also 385 
detected immune-signals of NPR1 and NPR2 in the epidermal KCs of healthy skin (Fig  386 
6A), and both signals were enhanced in AD skin (Fig 6A). We further analyzed the detailed 387 
distribution of these receptors by taking high resolution confocal images in epidermal KCs.  388 
Distinct localization of NPR1 and NPR2 were revealed in epidermal KCs of AD skin 389 
sections. NPR1 predominantly resided along the plasma membrane of KCs, whereas NPR2 390 
was detected both on plasmalemma and cytoplasm (Fig 6A). The enhanced labelling of 391 
NPR1 and NPR2 might not be simply due to the acanthosis, because we did observe 392 
increased immunoreactivity at single KC level by immunofluorescence staining. 393 
We further investigated BNP, NPR1 and NPR2 expression in the dermis of human skin. 394 
BNP expression was detected in the dermis of healthy skin, and its level appeared increased 395 
in dermal structures including secretory portion of sweat glands and blood vessel of AD 396 
skin (Fig 6B). Interestingly, NPR2 (Fig 6C, left panel) and NPR1 (not shown) did not seem 397 
to colocalize with PGP9.5 in these structures. NPR1 and NPR2 co-occurred on the dermal 398 
structures including secretory portion of sweat glands and blood vessel (Fig 6C middle and 399 
right panels). There was no obvious incremental labelling of NPR1 or NPR2 in the dermal 400 
structures (Fig 6C) and immune-reactive cells in AD skin compared to healthy skin 401 
(Supplementary Fig E5).  402 
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Consistently, using RT-PCR we also found Nppb transcripts were upregulated in lesional 403 
and non-lesional skin, compared with that in WT skin (Supplementary Fig E6 A). 404 
Moreover, BNP receptor NPR1 mRNA level was also increased in the lesional skin from 405 
IL-31Tg mice (Supplementary Fig E6 B).  406 
Taken together, these collective data suggest that BNP might be involved in promoting the 407 
dermatitis response through activated/upregulated receptor in AD. 408 
 409 
BNP induces release of IL-17A, chemokine (C-X-C motif) ligand 10 (CXCL10) and 410 
matrix metallopeptidase 9 (MMP9) from cultured human keratinocytes through 411 
activation of GSK3>JNK>ERK1/2≥P38 412 
KCs of AD patients exhibit a propensity to produce exaggerated cytokines, chemokines and 413 
proteases, which play major role in promoting and maintaining inflammation (27, 28). 414 
However, nothing is known about the influence of BNP on hKCs. We firstly investigated 415 
the possible BNP effect on hKCs. Cells in culture were exposed to BNP for 24 h before the 416 
supernatant was collected and used for proteome profiler human XL cytokine array, which 417 
allowed detecting 102 different cytokines simultaneously. An increase in IL-17A (~2.5 418 
folds), CXCL10 (~2 fold), and to a lesser degree, MMP9 was detected in the culture 419 
supernatant (Fig 7A). In contrast, significantly lower levels of cytokine release were 420 
triggered by the same dose of SP. In comparison, incubation of hKCs with 1 µM human 421 
CGRP peptide for 24 h only induced minimal CXCL5 release (Fig 7A). IL-17A is a critical 422 
cytokine involved in the pathogenesis of AD (29, 30). Its expression in KCs was reported 423 
(31-33) and detected in our primary culture (Supplementary Fig E4 B). CXCL10 mediates 424 
cell adhesion, migration and inflammatory infiltrates in AD (34). Elevated levels of IL-17A 425 
and CXCL10 are implicated in patients with AD (28, 29, 35).  Thus, peripheral BNP might 426 
promote the release of itch-related cytokines by acting on the KCs to propagate itch signals 427 
in AD.  428 
Subsequently, we investigated the signaling pathways involved in the activation of the KCs 429 
using phospho-kinase arrays on the cell lysate of hKCs harvested after exposure to 1 µM 430 
human BNP for 8 min. Glycogen synthase kinase 3 (GSK3), c-Jun N-terminal kinases 431 
(JNK) pan (JNK kinase family includes three proteins named JNK1, 2, 3), ERK1/2 and P38 432 
were significantly phosphorylated/activated by application of BNP. In contrast, ERK1/2, 433 
JNK and to a lesser extent GSK3 were activated by SP (Fig 7B).   IL-17A is considered to 434 
be a potent stimulator of further inflammatory mediator production, amplifying the 435 
inflammatory response. Therefore, using selective phosphor-kinase inhibitors, we 436 
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investigated which intracellular kinase was responsible for the BNP-mediated IL-17A 437 
release from hKCs. 1 µM P38α  inhibitor AL8697, GSK3 inhibitor SB216763 (inhibiting 438 
the activity of α and β isozymes of GSK-3), or JNK inhibitor JNK-IN-8, were incubated 439 
with cultured hKCs,  for 1 h prior to and during 24 h incubation with BNP before 440 
measuring IL-17A release using IL-17A ELISA kit. Inhibition of GSK3 by SB216763 441 
abolished the IL-17A release, whereas AL8697 only gave minor blockade (Fig. 7C). 442 
Because IL-17A is regarded as a key cytokine involved in the pathogenesis of AD (36, 37), 443 
targeting GSK3 may prove effective for the inhibition of itch transmission. 444 
  445 
BNP stimulates release of CCL20 through c-Jun activation in human monocyte-446 
derived dendritic cells (hDCs) 447 
We then assess a possible functional consequence of BNP on skin immune cells, hDCs, 448 
known to express BNP receptors (38). To do this, monocyte-derived hDCs were maintained 449 
in the presence of IL-4 and GM-CSF to allow their differentiation before incubating with 1 450 
µM human BNP for 24 h. We found CCL20 release was increased significantly by BNP, 451 
and this was not observed when incubated with 1 µM SP (Fig 7D). In the phospho-kinase 452 
array, BNP also activated c-Jun through phosphorylation, unlike SP which did not show 453 
any effect on c-Jun activation (Fig 7E). CCL20 level is strongly increased in lesional skin 454 
tissues with AD and it stimulates the migration of various immune cells (39-41). Thus, 455 
BNP induction of CCL20 release may constitute a novel neuron-immuno-modulatory 456 
mechanism that results in the activation of immature dendritic cells, which could contribute 457 
to the persistent itch.  458 
 459 
DISCUSSION 460 
AD patients experience a ‘vicious cycle of itching and scratching’ (42). The molecular 461 
basis for this phenomenon, however, is still unknown. Although it has recently been 462 
revealed that cytokines like IL-31 and IL4 or IL-13 play a role in immunity and itch 463 
transmission (8, 43, 44), it is currently unknown whether cytokines like IL-31 also regulate 464 
neuropeptide release from peripheral nerve endings thereby modulating neurogenic 465 
inflammation in AD (Fig 8). Understanding the importance of neuropeptide- and cytokine-466 
mediated intercellular communication would further explain not only the interplay between 467 
inflammation and itch, but also how this debilitating symptomatology of inflammation and 468 
itch may be therapeutically interrupted. Here, we show for the first time that peripherally 469 
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released BNP is implicated in AD pathophysiology through IL-31 stimulation and 470 
subsequent regulation of cytokine, chemokine and MMP9 release. Moreover, we show 471 
BNP also activates several major cell types in skin which are pivotal in AD itch 472 
transmission such as keratinocytes and dendritic cells (Fig 8). Thus, we have revealed 473 
another mechanism how TH2 cells simultaneously impact itch and neuro-inflammation.  474 
 475 
BNP was originally identified as an important contributor of central itch being released 476 
from central primary afferents to the dorsal horn of the spinal cord (19). Here we show for 477 
the first time that BNP is released from peripheral nerve endings upon stimulation by 478 
puritogens like IL-31 and histamine. These findings provide a new link between Th2 cells, 479 
mast cells and peripheral sensory nerves. Notably, this is unique to BNP as to other 480 
neuropeptides, such as CGRP and SP, because neither of them are synthesized nor released 481 
under the same conditions, despite both being linked to itch (45, 46). In addition, BNP 482 
together with its receptor, NPR1, are expressed in CGRP+ small sensory neurons (47). In 483 
fact, though traditionally viewed primarily as a pain mediator (48), SP has also been 484 
implicated as an itch mediator in AD, with increased numbers of SP+-nerve fibers found 485 
concomitantly with a decrease in cutaneous SP levels in lesional skin of AD (49, 50), and 486 
responsiveness to the NK1R antagonist aprepitant (45, 51). In particular, BNP-expressing 487 
sensory neurons are found not to be involved in acute, inflammatory or neuropathic pain 488 
(19, 52), unlike SP and CGRP.  Therefore, our findings further differentiate BNP from 489 
CGRP and SP and highlight its importance in the neuropeptide-mediated pathogenesis of 490 
AD-associated itch.  491 
 492 
Here, we show for the first time that IL-31RA and OSMRβ highly overlap in hDRGs, 493 
similar to the results observed previously in mDRGs (53). Moreover, in hDRGs IL-31 494 
elicited Ca2+-transient in ~50% ET-1-responsive neurons and ~2% of total neurons. Half of 495 
ET-1-responsive neurons also responded to histamine. To our knowledge, this is the first 496 
detailed characterization of human sensory sub-populations according their response to 497 
sequential and combined pruritogens. In contrast, IL-31 and ET-1 excited partly 498 
overlapping small subset of mDRG neurons.  In response to IL-31, Nppb transcripts in 499 
cultured mDRGs were specifically upregulated, but this was not found for Tac-1 or Calca. 500 
IL-31 was capable of eliciting ~2.7-fold increase of BNP release over the basal level. The 501 
elicited release was completely dependent on particular SNARE proteins, SNAP-25 and 502 
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VAMP1, which are also important for several other inflammatory diseases (54). In contrast 503 
to the minimal BNP release at resting condition, the IL-31-induced augmentation of 504 
peripheral BNP release may link to excessive itch in AD induced by a positive feed-back 505 
loop of amplifying itch mediators. This may also explain the difficulty to treat AD-506 
associated itch.  507 
 508 
Using deep sequence, we detected upregulation of Nppb transcripts in isolated TGs from 509 
the HDMs-treated PAR2 transgenic mice, which showed AD-like skin condition. 510 
Furthermore, our data confirm that the Nppb gene is implicated in severe AD conditions 511 
because mice with high clinical scores exhibit high levels of Nppb transcripts. Our findings 512 
provided the first evidence showing a functional association of BNP with severity of AD. 513 
Consistently, we established that Nppb transcripts in DRGs and skin of lesional IL-31Tg 514 
mice were also greatly upregulated. NPR1 transcripts were increased in lesional IL-31Tg 515 
skin. In fact,  upregulation of BNP in murine AD-like skin has also been reported by a 516 
recent finding using global transcriptome, which identified a significant Nppb upregulation 517 
(>3 fold) in oxazolone-challenged AD-like dermatitis mice skin (55).  518 
In a translational approach, we also provide  evidence for the importance of BNP in AD 519 
using skin from AD patient and healthy control subjects. We detected increased protein 520 
levels of NPR1 and NPR2 in epidermis, particularly in KCs. Moreover, enhanced 521 
expression of BNP in both epidermis and dermis of AD patient skin was revealed. In fact, 522 
immunostaining signal of BNP, NPR1 and NPR2 protein seemed to be increased in single-523 
cell level of KCs; however, we could not exclude that the possibility of the acanthosis 524 
might also contribute to the increment. The upregulated expression levels of BNP and its 525 
receptors in AD patients  suggest a role for the IL-31/BNP/BNPR-axis in peripheral itch 526 
amplification in AD patients.   527 
 528 
Although IL-31 rapidly induces itch in mice (7, 8) and is regarded as one of the major 529 
‘drivers’ of itch in AD, it failed to induce immediate itch responses in humans as shown in 530 
a recent study including both AD patients and healthy subjects monitored by skin prick 531 
testing (56). Though there is a possibility of insufficient amount of IL-31 being 532 
administered which failed to induce immediate itch response, the late onset of IL-31-533 
induced mild itch sensations might also be attributed to this cytokine exerting its pruritic 534 
effect indirectly via KCs and secondary mediators, rather than by a sole action on its 535 
receptors on cutaneous sensory nerves (56, 57). In addition, similar to IL-4 (44) IL-31 may 536 
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be a sensitizer in some patients and not a direct itch inducer. However, the variable 537 
expression levels of IL-31 and IL-31RA in AD patients may explain that some patients will 538 
respond more to IL-31 stimulation. Consequently, some patients may profit better from 539 
Anti-IL-31 therapy than others (11, 12). It will be interesting to learn as to whether IL-4 540 
and IL-13 are also linked to BNP release. 541 
We demonstrate that BNP acts as the downstream skin-derived effector of IL-31. In 542 
addition to its contribution to spinal processing of itch (19), excessive release of BNP from 543 
peripheral  sensory nerves stimulates NPR1 receptor to activate multiple intracellular 544 
signaling pathways in skin, thereby contributing to skin inflammation in AD. We found 545 
BNP activates GSK3 pathway and leads to the secretion of several important inflammatory 546 
or itch modulators, such as IL-17A, CXCL10 or MMP9 from skin KCs. BNP activates C-547 
Jun to release CCL20 from DCs. All of these cytokines are known to be increased in AD 548 
and represent an important potential component of the pathology of AD (58, 59). 549 
Upregulation of BNP receptor(s) in turn, could further augment secretion of the above 550 
important itch modulators from these cells. Thus, our results support a new pathway in 551 
which BNP is a peripheral contributor of IL-31-mediated neurogenic inflammation in AD, 552 
and establish the missing link between TH2-nerve mediated inflammation as well as 553 
pruritus.   554 
 555 
In conclusion, we describe a novel functional link between TH2 cells and sensory nerves 556 
through IL-31 and BNP, and give first evidence between a functional association of 557 
peripheral BNP in  AD using human and rodent DRGs, animal models and patient skin in a 558 
translational fashion. Indeed, Th2 cells, sensory neurons, keratinocytes and dendritic cells 559 
release a complex network of cytokines and chemokines establishing a local milieu and 560 
environment that favors AD skin inflammation. In this context, BNP seems to act as an 561 
important “relay center” for peripheral and central itch circuits to facilitate itch, but also 562 
neuroinflammation, in the pathogenesis of AD. We demonstrate that BNP acts through 563 
multiple mechanisms: 1) IL-31 modulates pruriceptive neurons to rapidly induce SNARE-564 
dependent release of BNP, and 2) IL-31 increases the synthesis of Nppb;  3) BNP receptors 565 
are upregulated in AD; 4) BNP signals through its upregulated receptors to directly activate 566 
multiple intracellular kinases in skin cells to elicit the release of itch-related pro-567 
inflammatory cytokines (Fig 8). Our findings provide new insights about BNP as an 568 
important regulator of neuro-inflammation as well as itch in the skin of AD, and close a 569 
missing link why the itch inflammatory skin disease AD has been also defined as 570 
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‘neurodermatitis’.  In addition, peripheral BNP signaling provides a new basis for the 571 
development of more effective therapies for AD and probably other skin diseases. 572 
 573 
FIGURE LEGENDS 574 
Fig 1. IL-31RA and OSMRβ co-occurred in a small population of hDRGs. (A, B) 575 
Representative immunofluorescence confocal images showing IL-31RA protein 576 
immunoreactivity only occurred in a subpopulation of neuronal cells in hDRG sections. 577 
Neuronal cells were stained by antibody against NeuN (A) or PGP9.5 (B). C, Co-staining 578 
of OSMRβ with PGP9.5 in hDRG section. D, Immunofluorescence staining of hDRG 579 
section showing IL-31RA and OSMRβ largely co-localised in a subset of neurons. 580 
Specimens were counterstained with DAPI to highlight all cell nuclei. Arrow pointed a 581 
neuron expressing OSMRβ but not stained strongly by IL-31RA antibody. E, Venn 582 
diagram depicts the relationship of IL-31RA+, OSMRβ+ and NeuN+ populations in hDRG 583 
section. Total neuron numbers were counted based on the dual labelling of both NeuN and 584 
DAPI. A total of 573 cells were imaged.  585 
 586 
Fig 2. Puritogens–induced calcium mobilization and characterization of IL-31–587 
responsive cells in hDRGs and mDRGs. A, Representative traces for calcium 588 
measurement after sequential pruritogen mediators application. Traces show individual cell 589 
responding to ET-1 only (top), histamine only (middle), ET-1 plus histamine (bottom). 590 
Notably, there are some ET-1–responsive neurons that also responded to histamine. B, 591 
Neurons responding to ET-1 only (top), IL-31 only (middle), ET-1 plus IL-31 (bottom). C, 592 
Venn diagrams for percentage of neurons that responded to puritogenic compounds. Total 593 
number of hDRGs recorded=100. D. Four representative traces of mDRG cells responsive 594 
to IL-31 and/or ET-1. Note that cell 1 responded to both IL-31 and ET-1; cell 2 only 595 
responded to ET-1, whereas cell 3 failed to respond to either IL-31 or ET-1; cell 4 is an IL-596 
31-responsive cell which did not respond to ET-1. Venn diagram showing relative 597 
proportions of mDRG neurons responsive to IL-31 and/or ET-1. A total of 335 mDRGs 598 
were recorded.  599 
  600 
Fig 3. Nppb is upregulated in sensory ganglia from HDM-treated Grhl3PAR2/ + mice 601 
and IL-31Tg mice. A, The FPKM for Nppb, NPR1, NPR2, IL-31, IL-31RA and OSMR 602 
gene from TGs of ipsilateral vs contralateral (ipsi vs contra) were analyzed by RNA-seq 603 
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and compared. Eight mice were treated with HDM on the right cheek and nothing on the 604 
left cheek, and the cheek biopsies were clinical scored using HE staining. Correlation 605 
coefficient between clinical score and fold change of Nppb is about 0.8, whereas for other 606 
genes analyzed the values are not significant. For these 8 mice the average of fold change 607 
of Nppb is 2.3. B, Representative HE staining images showing the severity of skin lesion 608 
from HDM-treated mice, compared with vehicle-treated WT control. Images were taken by 609 
10x magnification objective. C, FPKM analyzed by RNA-seq of the top 3 high clinical 610 
score mice (Score is 8, 7 and 7) show the Nppb gene was upregulated by 3.5 times (ipsi vs 611 
contra). Average of fold change for genes upregulated and reached significance were 612 
plotted.  A two-fold change in FPKM was deemed significant.  D, RT-PCR analysis of 613 
Nppb mRNA levels in DRGs isolated from lesional, non-lesional IL-31Tg or WT mice. 614 
Values were normalized to the housekeeping gene GADPH. The results (mean ± S.E.M.) 615 
are pooled data from multiple animals. Significant difference is indicated; * P<0.05; ** 616 
P<0.01. 617 
 618 
Fig 4. IL-31 induces the release and mRNA synthesis of BNP (but not CGRP or SP) 619 
from cultured mDRGs. Release of BNP (A), CGRP and SP (D) over 30 min was 620 
measured by their specific ELISA or EIA, and the increment of release after each treatment 621 
was plotted relative to the basal level. The amount in pg/ml in basal (LK) release is: 15.3 ± 622 
1.2 for BNP; 3.9 ± 0.9 for SP; 49.3 ± 11.8 for CGRP. LK, low potassium basal buffer; HK, 623 
high potassium stimulation buffer; HIS, histamine.  B, BNP release induced by various 624 
dose of IL-31 over 30 min.  C, Time-dependence of BNP release induced by 300 nM IL-31. 625 
E, RT-PCR for mRNA of Nppb, Calca and Tac-1 in cultured mDRGs after treatment with 626 
100ng/ml IL-31 for 6h. Data in A –E are presented as mean ± S.E.M. n ≥ 3 independent 627 
experiments. Significant difference is indicated; N.S. P>0.05; *P<0.05; ** P<0.01; *** 628 
P<0.001. F, Immunofluorescence study for cellular localization of CGRP (red) and BNP 629 
(green) after dual labelling of DRGs with each specific antibody and counterstained with 630 
DAPI (blue). Scale bars are indicated.  631 
 632 
Fig 5. IL-31-induced BNP release from cultured mDRGs requires SNARE proteins. A, 633 
Representative immunoblots show knock-down of SNAP-25 (S25), VAMP1 (V1) and 634 
VAMP7 (V7) protein expression in cultured DRGs using lentiviral shRNA particles. 635 
Syntaxin 1 (STX1) serves as an internal control in each blot. Non-targeted virus-treated 636 
samples were loaded to the gels for the comparison. B, Quantified plot demonstrates that 637 
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300 nM IL-31-elicited BNP release over 30min is inhibited after knockdown of S25 and V1 638 
but not V7. Data are presented as mean ± S.E.M. n ≥ 3 independent experiments. 639 
Significant difference between specific shRNA-treated cells and non-targeted controls is 640 
indicated; N.S. P>0.05; *** P<0.001.  641 
 642 
Fig 6. Immunohistochemical staining of BNP, NPR1 and NPR2 in the skin of human 643 
healthy control and AD patient. A. Representative fluorescent images show expression 644 
patterns of BNP, NPR1 and NPR2 in AD and healthy control skin. Note that epidermal 645 
keratinocytes layer of AD skin showed enhanced staining of BNP, NPR1 and NPR2 646 
compared to healthy control skin. Boxed areas in the middle panels are shown at higher 647 
magnification in right panels. B. Images show increased BNP staining in the dermal 648 
structures including secretory portion of sweat glands and blood vessel in AD skin 649 
compared with the healthy skin. C. NPR2 does not co-localize with nerve marker PGP9.5 650 
in the dermal structures, but highly co-localizes with NPR1. There is no obvious change of 651 
NPR1 and NPR2 expression in dermis between AD patient skin and control healthy skin. 652 
Scale bars are indicated. Paraffin-embedded human skin sections (n=10) from each donor 653 
of AD and healthy control subjects were stained for each condition. The white dotted lines 654 
denote the epidermal–dermal junctions.  655 
                                                                                        656 
Fig 7. Effect of BNP on cytokine/chemokine release and activation of intracellular 657 
phosphor-kinase. A, Release profile of cytokines from cultured hKCs detected by 658 
antibody array. Data from BNP-, SP- or CGRP-induced release were calculated relative to 659 
non-treated control (basal). B, Neuropeptide-induced activation of intracellular phosphor-660 
kinases. Data plotted are the ratio of phosphorylated signal obtained from neuropeptide-661 
treated cells relative to non-treated control. C, Percentages of inhibition by selective kinase 662 
inhibitors of BNP-induced IL-17A release from hKCs. D, CCL20 release from cultured 663 
hDCs induced by BNP or SP. E, Phosphorylation of intracellular c-Jun from hDCs after 664 
incubation with BNP or SP. Data are presented as mean ± S.E.M. n ≥ 3 independent 665 
experiments. Significant difference between stimulated and basal is indicated; * P<0.05; ** 666 
P<0.01; *** P<0.001.  667 
 668 
Fig 8. Schematic diagram illustrates an important communication link between IL-31 669 
and BNP, both of which are key players in the signaling pathways implicated in 670 
pruritus. Itch inducers such as IL-31 and histamine elicit BNP release via SNARE-671 
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controlled mechanism. Augmented release and synthesis by IL-31 of BNP might contribute 672 
to central and peripheral itch signaling. In contrast, CGRP and SP are not elicited by these 673 
puritogens. Released BNP subsequently increases IL-17A, CXCL10 and MMP9 release 674 
from keratinocytes; however, SP and CGRP only elicit minimum release of CXCL10 and 675 
CXCL5, respectively. BNP also mediates CCL20 from dendritic cells. Taken together, it is 676 
postulated that these released cytokines/chemokines modulate itch transmission and 677 
pathogenesis of AD.  678 
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Supplemental Materials and Methods 
Materials 
Skin samples from AD and healthy controls were bought from Tissue Solutions Ltd., Glasgow, 
Scotland. Enzyme immuno-assay (EIA) kits for CGRP and SP were bought from Bioquote; 
rabbit anti-syntaxin 1, rabbit anti-VAMP1 and 7 were bought from Synaptic Systems GmbH. SP, 
BNP, CGRP, histamine and ET-1, monoclonal antibody specific for CGRP (4901), rabbit anti-
PGP9.5, ELISA kit for BNP, shRNA lentiviral particles were bought from Sigma-Aldrich. 
Donkey anti-rabbit Alexa-488 and anti-mouse Alexa-594, donkey anti-goat Alexa594 and anti-
mouse Alexa 488 were supplied by Jackson ImmunoResearch. Ibidi GmbH provided the culture 
chambers. Rabbit anti-BNP antibody (G-011-23) was purchased from Phoenix Pharmaceuticals, 
Inc. and monoclonal anti-SNAP-25 (SMI 81) was bought from Sternberger Monoclonals Inc. 
Mouse monoclonal anti-PGP9.5 (Ab8189), -NPR2  (Ab55724), rabbit anti-NPR1 (Ab14356), -
BNP (Ab19645), -NeuN antibody (Ab177487) and IL-17A ELISA kit were provided by Abcam; 
AL8697, goat anti-IL-31RA, mouse anti-OSMRβ, CCL20 ELISA kit, proteome profiler™ 
human XL cytokine array, human phospho-kinase array kits and IL-17A antibody (AF-317-NA) 
were bought from R&D Systems; SB216763 was purchased from Tocris; JNK-IN-8 was 
obtained from Axon Medchem. Rabbit anti-NPR1 antibody (NBP1-31333) was purchased from 
Novus Bio. Adult normal hKCs and hDCs and their culture medium were bought from Lonza.  
Human DRG paraffin sections were bought from Zyagen. Alexa 594 conjugated mouse anti-
human Vimentin antibody, Alexa 488 conjugated mouse anti-human CD4 and Alexa 488 
conjugated mouse anti-human CD80 were purchased from BioLegend. Mouse C57 DRG 
sections were purchased from Amsbio. 
HDM application on Grhl3PAR2/ + mice model 
The Grhl3PAR2/ + mice were maintained in C57BL6/J-129X1/SvJ mixed strain and used for the 
experiments as D model. We used mite-extract ointment/house dust mite (HDM) (BiostirAD 
cat#303-34131) on the right cheek to induce severe skin lesion. For HDM treatment, 8 mice were 
shaved on cheek one day prior to application. On the application day, 4% SDS was always 
rubbed on shaved cheek area 2 h before HDM application. HDM was applied on right cheek 
twice a week with at least a 3 day resting period prior to the next application for 6 weeks. At the 
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end of the treatments we euthanized the mice and harvest lesional, perilesional and non-lesional 
skin for pathologic diagnosis using HE staining to measure the clinical score, and trigeminal 
ganglia were harvested for gene expression experiment.   
RNA-Seq  
For gene expression experiment, TGs were harvested from Grhl3PAR2/ + mice. Total RNA was 
isolated from right TG (ipsilateral) and left TG (contralateral) with TRIzol Reagent (Life 
technologies cat#15596). Then mRNA library was made with Ovation Universal RNA-Seq 
System (NuGEN cat#0343). Samples were subsequently sequenced on the HiSeq2500 (illumine).  
 
Quantitative real time PCR 
DRGs were isolated from adult C57Bl6 mice (6-8 weeks old) and treated with 3 mg/ml 
collagenase (Sigma Aldrich) and 0.25 mg/ml trypsin (PAA) for 30 minutes. DRGs were 
triturated for dissociation and were plated onto cell culture dishes coated with poly-L-lysine (100 
mg/ml; Sigma Aldrich) and laminin (5 mg/ml; Sigma Aldrich) in MEM supplemented with 10% 
horse serum, 1% penicillin/streptomycin, 1% vitamins, 1% N2-supplement and 2% B27-
supplement. After overnight rest, DRG neurons were treated with 100 ng/ml murine IL-31 
(ZymoGenetics) for 6 h. The quantitation of mRNA levels was performed by real time 
fluorescence detection using Absolute SYBR Green ROX mix (ABI).  
The primers used for both DRGs and skin were as follows: mNppb forward, 5´- 
gtcagtcgtttgggctgtaac-3´; mNppb reverse, 5´-agacccaggcagagtcagaa-3´; mCalca forward, 5´-
agcaggaggaagagcagga-3´; mCalca reverse, 5´- cagattcccacaccgcttag-3´;mTac1 forward, 5´- 
agcctcagcagttctttgga-3´; mTac1 reverse, 5´- tctggccatgtccataaagag-3´.  Primer and probe specific 
for 18S RNA and glyceraldehyde 3-phosphate dehydrogenase (GADPH) were obtained from 
Life technologies (Darmstadt, Germany) and Eurofins Genomics (Germany). Target gene 
expression was analyzed on an ABI Prism 7000 supplemented with SDS 1.2.3 software and the 
expression profile was normalized using the 18S or GADPH expression. In the case of mouse 
tissue, the primers used were: mNPR1 forward, 5´- ttccacactggaggttctggct-3´; mNPR1 reverse, 
5´- ctctgagaccagctccttttcc-3´. 
 
BNP, CGRP and SP release assay 
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In order to investigate BNP, SP and CGRP release, DRG were isolated from postnatal d5 
C57BL/6 mice and dissociated by collagenase I as detailed (1). Neurons were cultured in the 
presence of cytosine β-d-arabinofuranoside (AraC, Sigma) and nerve growth factor (NGF) 100 
ng/ml for 7 DIV (days in vitro). Basal low potassium (LK) release buffer (mM; 22.5 HEPES, 
135 NaCl, 3.5 KCl, 1 MgCl2, 2.5 CaCl2, 3.3 glucose and 0.1% BSA, pH 7.4) was added into each 
well, followed by a 30-min incubation at 37 °C (2).  Cells were then stimulated for 30 min or as 
indicated in Figures by high potassium (HK, 60 mM K+ , isotonically balanced with NaCl), 1 µM 
histamine, or 300 nM IL-31 (Zymogenetics). Release of BNP, CGRP or SP was quantified using 
their ELISA or EIA kit.  
 
Measurement of intracellular Ca2+ concentration 
For the hDRG calcium measurement, cells in culture were loaded with 5 µM Fluo 8-AM (AAT 
Bioquest 21081) containing 0.1% Pluronic F-127 (Sigma P2443) for 20 min. Extracellular 
solution contained in mM: 145 NaCl, 3 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose adjusted 
to pH 7.4 with NaOH. Fluo-8-loaded cells were excited at 480 nm and emission was collected at 
520 nm with a pcoEDGE sCMOS camera (PCO) mounted on an inverted microscope (Olympus 
IX71). Following a baseline period of 60 s, ET-1 (30 nM); Histamine (10 µM); IL-31 (300 nM) 
were applied sequentially, for 60 s. each, followed by washout for 5 min. Images were acquired 
at 0.2 Hz. In the case of mDRGs, 3 µM Fluo 4-AM was used and images were acquired by a 
Zeiss LSM710 confocal microscope (Carl Zeiss MicroImaging) with argon laser at 2 sec 
intervals.  
 
Immunofluorescence staining 
For cellular localization of CGRP and BNP in cultured mDRGs, cells were processed by dual 
labelling overnight at 4°C with 1:100 rabbit anti-BNP antibody (G-011-23; Phoenix 
Pharmaceuticals, Inc.) and 1:200 mouse anti-CGRP antibody (clone 4901, Sigma). Secondary 
donkey anti-rabbit Alexa Fluor 488 (1:2000) and anti-mouse Alexa Fluor 594 (1:2000) were 
added for 1 h at room temperature.  
Human DRG and skin paraffin sections (15µm) were deparaffinized, rehydrated before 
permeabilized in phosphate-buffered saline with 0.2% Triton X-100 (PBS-T) and then incubated 
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in PBS containing 5% normal donkey serum (blocking solution) at RT for 1 h. Specimens were 
then incubated with primary antibodies in blocking solution (4 °C, overnight). For human DRG 
sections, primary antibodies were used at the following dilutions: goat anti-IL-31RA 1:100 
(R&D Systems); mouse anti-OSMRβ 1:100 (R&D Systems); mouse monoclonal PGP9.5 
antibody 1:40 (Abcam) or rabbit anti-PGP9.5 1:1000 (Sigma); rabbit anti-NeuN antibody 1:500 
(Abcam). The sections were washed in PBS and were incubated in donkey anti-goat Alexa 594 
and donkey anti-mouse Alexa 488 (Jackson ImmunoResearch) or donkey anti-rabbit Alexa 488 
diluted 1:2000 with blocking solution (RT, 1 h). For human skin sections (15µm), we used rabbit 
polyclonal to BNP (Abcam, 1:1000), rabbit polyclonal to NPR1 (Novus Bio, 1:500) or mouse 
monoclonal to NPR2 (Abcam, 1:80), rabbit anti-PGP9.5 (Sigma).  
For hKC staining, cultured cells were fixed in 3.7% paraformaldehyde in PBS, permeabilized by 
0.1% Triton X-100 and then blocked in 5% normal donkey serum (blocking solution) at RT for 1 
h before samples were incubated with the primary antibodies overnight at 4 °C. Antibodies used 
are: rabbit anti-NPR1 1:500 (Abcam), rabbit anti-BNP 1:1000 (Abcam), mouse monoclonal to 
NPR2 1:80 (Abcam), mouse monoclonal to K14 1:200 (cytokeratin 14; Ab7800), goat anti-IL-
17A 1:100 (R&D),  Alexa 594 conjugated mouse anti-human Vimentin antibody 1:200, Alexa 
488 conjugated mouse anti-human CD4 1:200 and Alexa 488 conjugated mouse anti-human 
CD80 1:200. The specimens were washed in PBS and were incubated in donkey anti-goat 
Alexa594 or donkey anti-goat 488 and donkey anti-mouse Alexa 488 or donkey anti-rabbit 
Alexa 488  (Jackson ImmunoResearch) diluted 1:2000 with blocking solution (RT, 1 h).  
To check specificity of BNP and CGRP antibodies, rabbit anti-BNP antibody (G-011-23; 
Phoenix Pharmaceuticals, Inc.) was pre-incubated with or without mouse BNP-45 peptide 
(Phoenix Europe) at 1:10 molar ratio. Likewise, mouse anti-CGRP antibody (clone 4901, Sigma) 
was pre-incubated with or without rat α-CGRP peptide (Sigma) at 1:10 molar ratio.  Antibodies 
alone or with their antigen mixtures were incubated at overnight at 4°C. Mouse C57 DRG 
sections purchased from Amsbio were formalin-fixed, permeabilised in PBS with 0.1% Triton X-
100 and blocked in PBS containing 5% normal donkey serum.  Immunofluorescence labelling 
was performed overnight at 4°C with 1:100 rabbit anti-BNP antibody, 1:200 mouse anti-CGRP 
antibody alone or antibody pre-incubated with its antigen (as specified in figure legends) in 
blocking solution. After extensive wash, secondary donkey anti-rabbit Alexa Fluor 488 (1:2000) 
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and anti-mouse Alexa Fluor 594 (1:2000) diluted in blocking solution were added for 1 h at room 
temperature.  
After the final wash of the secondary antibody, specimens were mounted onto slides using 
prolong anti-fade reagents contain (4',6-diamidino-2-phenylindole) DAPI (ThermoFisher 
Scientific). Images were taken by a Zeiss LSM710 confocal microscope (Carl Zeiss 
MicroImaging) with argon and helium/neon lasers. Images were acquired by Zen software 
(Universal Imaging, Göttingen). 
Lentivirus-mediated knockdown of SNARE proteins 
 At 7 DIV, mDRGs were incubated in medium containing shRNA lentiviral particles that 
specifically target to SNAP-25, VAMP1, or VAMP7, or non-targeted PLK0.1-puro particles 
(400 transducing units/well), and cultured as above. After 7–10 days in culture, cells were 
stimulated before being harvested in lithium dodecyl sulfate sample buffer and analysed by 
western blotting. Targeted genes/protein IDs and validated sequences for shRNA lentiviral 
transduction particles were as follows:  
NM_011428,SNAP-25: 
CCGGCATCAGGACTTTGGTTATGTTCTCGAGAACATAACCAAAGTCCTGATGTTTTT
G 
NM_009496,VAMP1: 
GTACCGGCATCGTGGTAGTGATTGTAATCTCGAGATTACAATCACTACCACGATGTT
TTTTG;  
NM_011515,VAMP7: 
CCGGGCACAAGTGGATGAACTGAAACTCGAGTTTCAGTTCATCCACTTGTGCTTTTT
G 
Culture of human primary epidermal keratinocytes (hKCs) and human monocyte-derived 
dendritic cells (hDCs), cytokine antibody array and phosphor-kinase array 
 Human primary KCs were cultured in the KBM-Gold™ medium with KBM-Gold SingleQuot 
keratinocytes supplement (Lonza). All the release from hKCs was performed in hydrocortisone-
free medium with or without stimulation compound. Human DCs were cultured by in vitro 
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differentiation of CD14+ monocytes (subpopulation of peripheral blood mononuclear cells) using 
LGM-3™ Lymphocyte Growth Medium + 50 ng/ml GM-CSF + 50 ng/ml IL-4 (Lonza). Cells 
were maintained in the above medium for 3 d before use. Release was performed in plain LGM-
3™ Lymphocyte Growth Medium in the presence of neuropeptides. After release, cell culture 
supernatant was collected for proteome profiler human cytokine antibody array according 
manufacturer protocol. Briefly, the array membranes were blocked and then incubated with the 
sample for overnight at 4 °C. The membranes were washed three times and then incubated in 
diluted primary antibodies for 1 h at room temperature. After washing, membranes were 
incubated with diluted HRP-conjugated streptavidin for 1 h at room temperature and membranes 
were developed using enhanced chemiluminescence reagent. Images were captured, 
densitometrically scanned. Each cytokine spot was analyzed using Image J software and the 
average of positive controls of each treatment was set to 100 and all cytokines of the treatment 
were compared to that. The resultant values from the treatment were calculated relative to the 
non-treated control to give the fold of increase. 
For the kinase array, cells grown in T175 flasks were treated with or without neuropeptides for 8 
min and cells were lysed for intracellular phosphor-kinase array according to manufacturer 
protocol.  
 
Phospho-kinase inhibitors treatment 
1 µM selective p38 MAPK inhibitor AL8697, 1 µM selective inhibitor of the α and β isozymes 
of GSK-3 SB216763 or 1 µM selective JNK1/2/3 inhibitor JNK-IN-8 was applied to the cultured 
hKCs 1 h prior to and during 24 h incubation with 1 µM BNP or 1 µM SP in serum free and 
hydrocortisone-free medium to release the cytokines. The supernatant was collected for assay of 
cytokines using antibody array or ELISA as detailed above.  
 
Reference for Supplementary Methods 
 
1. Malin SA, Davis BM, and Molliver DC. Production of dissociated sensory neuron cultures and 
considerations for their use in studying neuronal function and plasticity. Nature protocols. 
2007;2(1):152-60. 
2. Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, Lawrence GW, and Dolly JO. 
Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal 
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sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive 
potential. The Journal of neuroscience : the official journal of the Society for Neuroscience. 
2009;29(15):4981-92. 
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Supplementary Figure Legends 
Fig E1.  Average Nppb value FPKM from contralateral cheeks of top 3 clinical scored 
Grhl3PAR2/ + 
mice was not significantly different from that of the WT mice. Statistical analysis 
demonstrated that Nppb FPKM from the non-treated contralateral cheeks of Grhl3PAR2/+ mice 
did not significantly differ from the values of Vaseline-treated ipsilateral cheeks or non-treated 
contralateral cheeks in WT mice. However, HDM induced significantly higher Nppb FPKM in 
ipsilateral cheeks compared with contralateral cheeks in Grhl3PAR2/ + mice. Average values of 
FPKM are plotted. P <0.05 indicates significance. 
 
Fig E2. IL-31-induced Nppb mRNA synthesis in cultured mouse DRGs is time- and 
concentrationdependent. 
A, RT-PCR analysis of Nppb mRNA synthesis in mDRGs upon treatment with various 
concentrations of IL-31 for 30 min. B, Time course of Nppb mRNA synthesis analysed by RT-
PCR after treatment with 300 nM IL-31. Data are expressed relative to GAPDH and presented as 
mean ± S.E.M. n = 3 independent experiments. N.S.>0.05; ** P<0.01; *** P<0.001. 
 
Fig E3. Antibody absorption test confirmed BNP and CGRP antibodies’ specificities. A, 
Confocal images show that fluorescence signal of CGRP in mDRG sections was greatly reduced 
by pre-absorption of CGRP antibody with α-CGRP peptide. B, Immunofluorescence images 
showing staining pattern in mDRG sections using BNP antibody in comparison with its antigen 
absorbed control. 
 
Fig E4. Characterization of cultured human primary keratinocytes (hKCs) using 
immunecytochemical 
staining. A, Immunofluorescene staining of BNP, NPR1 and NPR2 as well as proliferative 
keratinocyte marker Keratin 14 (K14) in hKCs. BNP was undetectable. NPR1 and NPR2 showed 
distinct distribution pattern. B, IL-17A immune-signal is detected in cultured hKCs. K14 and 
vimentin were expressed in all the cultured cells. Immuno-cell markers, CD4 and CD80 antibody 
staining signal is either absent or negligible. 
 
Fig E5. Immunohistochemical dual staining of NPR1 and NPR2 in skin of human healthy 
control and patient with AD. Representative fluorescent images at low magnification (left 
column panels) and high magnification (right column panels) of NPR1 and NPR2 in healthy 
control (A) and AD patient skin (B). NPR1 and 2 are highly localized in some cells in the dermis. 
Specimens were counter-stained with DAPI. 
 
Fig E6. RT-PCR analysis of Nppb and NPR1 mRNA levels in skin of IL-31Tg or WT mice. 
RT-PCR analysis of Nppb mRNA (A) or NPR1 mRNA (B) levels in skin isolated from lesional, 
nonlesional IL-31Tg or WT mice. Values were normalized to the housekeeping gene GADPH. 
The results (mean ± S.E.M.) are pooled data from multiple animals. Significant difference is 
indicated; N.S. P>0.05; * P<0.05; ** P<0.01, *** P<0.001. 
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Average Nppb value FPKM from contralateral cheeks of top 3 clinical scored Grhl3PAR2/ + 
mice was not significantly different from that of the WT mice.   Statistical analysis 
demonstrated that Nppb FPKM from the non-treated contralateral cheeks of Grhl3PAR2/+ mice 
did not significantly differ from the values of Vaseline-treated ipsilateral cheeks or non-treated 
contralateral cheeks in WT mice. However, HDM induced significantly higher Nppb FPKM in 
ipsilateral cheeks compared with contralateral cheeks in Grhl3PAR2/ + mice. Average values of 
FPKM are plotted. P <0.05 indicates significance. 
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IL-31-induced Nppb mRNA synthesis in cultured mouse DRGs is time- and concentration-
dependent. A, RT-PCR analysis of Nppb mRNA synthesis in mDRGs upon treatment with various 
concentrations of IL-31 for 30 min. B, Time course of Nppb mRNA synthesis analysed by RT-PCR 
after treatment with 300 nM IL-31. Data are expressed relative to GAPDH and presented as mean ± 
S.E.M. n = 3 independent experiments. N.S. P>0.05; ** P<0.01; *** P<0.001.  
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Fig  E3  
Antibody absorption test confirmed BNP and CGRP antibodies’ specificities.  A, 
Confocal images show that fluorescence signal of CGRP in mDRG sections was 
greatly reduced by pre-absorption of CGRP antibody with α-­‐CGRP	   pepSde. B, 
Immunofluorescence images showing staining pattern in mDRG sections using BNP 
antibody in comparison with its antigen absorbed control. 
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Characterization of cultured human primary keratinocytes (hKCs) using immune-
cytochemical staining. A, Immunofluorescene staining of BNP, NPR1 and NPR2 as well as 
proliferative keratinocyte marker Keratin 14 (K14) in hKCs. BNP was undetectable. NPR1 
and NPR2 showed distinct distribution pattern. B, IL-17A immune-signal is detected in 
cultured hKCs. K14 and vimentin were expressed in all the cultured cells. Immuno-cell 
markers, CD4 and CD80 antibody staining signal is either absent or negligible.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Fig  E5 
He
al
th
y	  
sk
in
	  d
er
m
is
	  	  
NPR1 +NPR2+DAPI 
AD
	  sk
in
	  d
er
m
is
	  
Immunohistochemical dual staining of NPR1 and NPR2 in skin of human healthy control 
and patient with AD. Representative fluorescent images  at low magnification (left column 
panels) and high magnification  (right column panels) of NPR1 and NPR2 in healthy control 
(A) and AD patient skin (B). NPR1 and 2 are highly localized in some cells in the dermis. 
Specimens were counter-stained with DAPI.  
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RT-PCR analysis of Nppb and NPR1 mRNA levels in skin of IL-31Tg or WT mice. RT-PCR 
analysis of Nppb mRNA (A) or NPR1 mRNA (B) levels in skin isolated from lesional, non-
lesional IL-31Tg or WT mice. Values were normalized to the housekeeping gene GADPH. The 
results (mean ± S.E.M.) are pooled data from multiple animals. Significant difference is indicated; 
N.S. P>0.05; * P<0.05; ** P<0.01, *** P<0.001. 
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